SCHEMBL26093055

SCHEMBL26093055

CC(C)(C)OC(=O)N1CC2(CNCCN2Cc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
GPR119 Q8TDV5 2/20 0.44
STS P08842 1/20 0.43
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
EPHX2 P34913 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TP53 P04637 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395081 0.93 OPRD1 (0.46) OPRD1OPRK1GPR119STSMAPK1
SCHEMBL14902797 0.85 EPHX2 (0.55) OPRD1OPRK1GPR119STSJAK2
SCHEMBL26089523 0.83 OPRD1 (0.46) OPRD1OPRK1GPR119STSJAK2
SCHEMBL4879579 0.82 OPRD1 (0.50) OPRD1OPRK1GPR119STSJAK2
SCHEMBL26093708 0.82 MEN1 (0.45) STSMAPK1SMN1; SMN2PARP1
SCHEMBL1049597 0.81 OPRD1 (0.49) OPRD1OPRK1GPR119STSJAK2
SCHEMBL322502 0.80 OPRD1 (0.48) OPRD1OPRK1GPR119STSEPHX2
SCHEMBL20722852 0.79 OPRD1 (0.45) OPRD1OPRK1GPR119STSJAK2
SCHEMBL1555874 0.79 OPRD1 (0.49) OPRD1OPRK1EPHX2HDAC1HDAC8
SCHEMBL26427466 0.77 MAPK1 (0.43) GPR119MAPK1KDM4EPKMRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 US disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 EP disclosed
CN-118556059-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-08-27 CN disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA OPRD1 1898/4885OPRK1 1700/4885GPR119 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.